Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report

INTRODUCTION: Teneligliptin, an antidiabetic agent classified as a class III dipeptidyl peptidase-4 (DPP-4) inhibitor, has a unique structural feature that provides strong binding to DPP-4 enzymes. We investigated the efficacy and safety of switching patients with type 2 diabetes mellitus (T2DM) who...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Ther
Main Authors: Kim, Hae Jin, Kim, Young Sik, Lee, Chang Beom, Choi, Moon-Gi, Chang, Hyuk-Jae, Kim, Soo Kyoung, Yu, Jae Myung, Kim, Tae Ho, Lee, Ji Hyun, Ahn, Kyu Jeung, Kim, Kyoungmin, Lee, Kwan Woo
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612358/
https://ncbi.nlm.nih.gov/pubmed/31079357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0628-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados